{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:48:32Z","timestamp":1792082912401,"version":"4.4.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1177\/1352458518757931","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T05:25:18Z","timestamp":1519277118000},"page":"1159-1161","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis \u2013 No"],"prefix":"10.1177","volume":"24","author":[{"given":"Mitchell T","family":"Wallin","sequence":"first","affiliation":[{"name":"VA Multiple Sclerosis Center of Excellence-East, Washington, DC, USA"},{"name":"School of Medicine, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"bibr1-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0557-4"},{"key":"bibr2-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"bibr3-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331"},{"key":"bibr4-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4011"},{"key":"bibr5-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"bibr6-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"bibr7-1352458518757931","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"bibr8-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e24373"},{"key":"bibr9-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867"},{"key":"bibr10-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.103"},{"key":"bibr11-1352458518757931","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001608"},{"key":"bibr12-1352458518757931","unstructured":"Tolerability and safety of switching from rituximab to ocrelizumab in patients with relapsing forms of multiple sclerosis, NCT02980042, University of Colorado, Denver, CO, Clinicaltrials.gov (accessed 13 January 2018)."}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458518757931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458518757931","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458518757931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:53:55Z","timestamp":1777694035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458518757931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1177\/1352458518757931"],"URL":"https:\/\/doi.org\/10.1177\/1352458518757931","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}